Efanesoctocog alfa represents a novel investigational recombinant factor VIII therapy for patients with haemophilia A
A press release from manufacturer Sanofi, has described how their novel, investigative agent, efanesoctocog alfa, is effective in the management of patients with haemophilia A.
In those with severe haemophilia A, levels of endogenous plasma factor VIII are below 1% and such individuals can experience recurrent bleeds and which are treated using replacement therapy with clotting factor concentrates as prophylaxis or on-demand therapy for bleeding. Within the plasma, the majority of Factor VIII circulates attached to von Willebrand factor and this modulates its half-life and provides protection from degradation. However, coupling of both proteins imposes constraints on the half-life of factor VIII. Efanesoctocog alfa represents a novel form of factor VIII replacement that is physically decoupled from endogenous endogenous von Willebrand factor, thereby extending the half-life of factor VIII. Although not yet approved, the available data for efanesoctocog alfa and which was published in the New England Journal of Medicine (NEJM), concluded that it provided superior bleeding prevention compared to pre-study prophylaxis, as well as the achievement of near to near-normal factor VIII activity and improvements in physical health.
In the phase 3 trial (XTEND-1) which is the subject of the press release, efanesoctocog alfa was able to deliver normal or near-normal (> 40%) factor VIII activity for the majority of the week with a single, once weekly dosing. In fact, the mean annualised bleeding rate (ABR) was 0.71 (95% CI 0.52 – 0.97) yielding a 77% reduction compared to prior prophylaxis with factor VIII (P < 0.001) based on an intra-subject comparison.
Other data showed that efanesoctocog alfa led to significant (compared to baseline) improvements in physical health, pain intensity and joint health after 52 weeks. Additionally, the product was well tolerated and inhibitor development to factor VIII was not detected and treatment-emergent adverse effects, in greater than 5% of participants were headache, arthralgia, fall and back pain.
Efanesoctocog alfa is currently under FDA review and regulatory submission in the EU is anticipated in the second half of 2023.